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Abstract
Background: Academic clinical trials play a fundamental role in the development of new treatments, the
repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments
increasingly targeted at molecular subtypes, and with priority placed on developing new treatments for rare
tumour types, the need for international trial participation to access sufficient patient numbers for successful trial
conduct is growing. However, lack of harmonisation of international legal, ethical and financial systems can make
this challenging and the cost and effort of conducting trials internationally can be considered prohibitive,
particularly where the sample size is comparatively small.
Methods: The Institute of Cancer Research – Clinical Trials and Statistics Unit (ICR-CTSU) is a UK-based academic
clinical trials unit that specialises in the design, conduct and analysis of clinical trials of cancer treatments with an
expanding portfolio of trials in molecular subtypes of breast and urological cancers and in other rare cancer types.
Implementing appropriate mechanisms to enable international participation has therefore been imperative. In this
article, we explain how we have approached the challenges involved and describe examples of successful
international trial conduct, achieved through robust collaborations with academic and industry partners.
Conclusion: Conducting academic trials internationally is challenging but can and should be achieved through
appropriate governance mechanisms and strong collaborations.
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Background
In the era of precision medicine and with priority placed
on developing new treatments for rare cancers, the need
for international participation in academic clinical trials is
increasing. However, lack of harmonisation of inter-
national legal, ethical and financial systems can make this
challenging and the cost and effort of conducting trials
internationally can be considered prohibitive, particularly
where the sample size is comparatively small [1–5]. In this
article we describe the progress, success and challenges
faced by a UK-based, academic clinical trials unit, The In-
stitute of Cancer Research – Clinical Trials and Statistics
Unit (ICR-CTSU) to manage academically sponsored
non-commercial international clinical trials.
Main text
Academic clinical trials units
There is no doubt that academic clinical trials make an
important contribution to improvements in outcomes
for cancer patients [6, 7]. ICR-CTSU is a UK university-
based clinical trials unit that specialises in the design,
conduct and analysis of academically sponsored cancer
clinical trials. ICR-CTSU is a UK Clinical Research Col-
laborative registered clinical trials unit [8] and one of 15
units recognised by the National Cancer Research Insti-
tute for professional specialism in the development and
delivery of cancer trials [9]. Comprising approximately
90 staff, ICR-CTSU provides academic leadership in tri-
als, providing expert advice on scientific methods (statis-
tical design and analysis) and also information
governance, good clinical practice and data linkage. ICR-
CTSU is responsible for all aspects of trial conduct in-
cluding securing trial funding, protocol development,
obtaining regulatory and ethics approvals, site selection
and initiation, monitoring, pharmacovigilance and data
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analysis. ICR-CTSU receives core funding from the UK
cancer charity, Cancer Research UK, which provides
support to core senior multidisciplinary staff. Individual
trial teams (trial managers, data managers, statisticians,
programmers) and research procedures (trials unit and
participating site research costs) are funded by charity
and government trial-specific project grants and educa-
tional grants from industry.
Sponsorship
Initial considerations around ICR-CTSU leadership of
international trials focused on models of sponsorship.
Whilst ICR traditionally favoured co-sponsorship, with
allocation of sponsor responsibilities between ICR and
the host institution of the chief investigator, this model
was not widely recognised outside of the UK. This fun-
damental issue was resolved by ICR defining a frame-
work for sole sponsorship of international clinical trials.
In order to accept the role of international sponsor, ICR
requires that defined criteria are met, including that
there is a full justification for opening the trial inter-
nationally; the trial is already open and recruiting in the
UK; national insurance arrangements are confirmed and
ICR-CTSU must work with a collaborative group or lead
site in each country who are willing to take on certain
delegated national responsibilities.
Country selection
The number of countries participating in an inter-
national trial has a considerable resource impact. There-
fore, the decision of how many and which countries will
participate is important. A small number of carefully se-
lected countries are usually approached initially to par-
ticipate. Factors affecting the choice of country include
access to sufficient patient numbers, availability of clin-
ical leadership and trials infrastructure, no known legal
barriers, previous successful collaborations between the
national collaborative group and ICR-CTSU and a
proven track record of delivering multicentre inter-
national trials.
Delegating country-specific sponsor responsibilities
The first task in each new proposed country is to iden-
tify a suitable collaborative group and confirm they can
perform the required national delegated responsibilities.
Although a seemingly simple task, this can take consid-
erable time, from 6 months to in excess of 2 years, and,
in some instances, the study is not able to proceed be-
cause agreement cannot be reached on all required
responsibilities.
There are various reasons for the lengthy negotiations.
For example, the standard scientific review process is
often a two-stage process of ‘outline’ followed by ‘full’
application, where each application is reviewed at a
formal scheduled meeting. Once scientific approval is in
place, extensive operational negotiations with a different
team often follow to establish local regulatory require-
ments and ensure the group can meet sponsor specifica-
tions for trial management and oversight.
The structure, level of resource, funding opportunities
and operational experience of each collaborative group
varies widely meaning a unique model of collaboration
is often required for each country, and this takes time to
establish and define contractually.
When trying to set up a trial in one country, following
lengthy discussions around the collaboration model it
became apparent that the collaborative group did not
have the infrastructure to support certain delegated tasks
such as on-site monitoring, so an alternative collabora-
tive group had to be approached and the review process
started again. In another country, although the collab-
orative group was able to take on some responsibilities,
a contract research organisation (CRO) had to be
appointed to take on others.
Although planning discussions are often lengthy, our
experience is that they result in successful and efficient
collaborations. Delegation of country-specific sponsor
responsibilities ensures the collaborative group is re-
sponsible for all tasks that require local language, know-
ledge and experience, such as national ethical and
regulatory submissions and approvals, country-specific
safety reporting and local on-site monitoring.
Insurance
In almost all instances, the most extensive discussions
with the international collaborative groups relate to de-
termining the national requirements for clinical trials in-
surance and arranging for additional country-specific
cover to be put in place. Whilst in the UK a national in-
demnity scheme for clinical negligence claims exists,
professional indemnity arrangements for clinical re-
search may not be as clearly defined in other countries.
A separate clinical trial insurance policy (in addition to
the no-fault policy required by the EU Directive) is often
required in third (non-EU) countries, and as the aca-
demic collaborative groups often already have this in
place, the set-up process can be more straightforward
and considerably faster outside of the EU.
Collaborations with North America
UK sponsorship of clinical trials in the US remains diffi-
cult due to the differing regulatory, data protection and
insurance requirements [10, 11]. For a UK academic
sponsor, the additional costs of requisite legal consult-
ancy and insurance for US participation can be prohibi-
tive. EU concerns regarding data protection safeguards
in the US exist making transfer of patient level data from
the EU to the US extremely challenging. This does not
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have to prevent UK-led non-commercial trials running
in the US and indeed ICR-CTSU currently collaborates
with a US academic group to run the same trial in the
UK and US, with parallel protocols. Separate databases
exist for UK and US patients but the data are pooled for
analysis in the UK and overseen by a single independent
data monitoring committee. Whilst this circumvents the
regulatory hurdles, it provides its own complexities in
terms of consistency of trial conduct and data collection
so robust processes for oversight and control via global
oversight committees, comprehensive agreements and
clear operating procedures are required.
Funding international clinical trials
The source of national funding is also a point for exten-
sive discussion. ICR-CTSU central trial management
costs are usually met by charitable grant funding, but
such funding may not be sufficient to support inter-
national trial management costs. As such, each national
collaborative group may be required to secure funding
for their local activities and if applicable, the responsibil-
ity for this is delegated to the national collaborative
group. Delegation of this task allows the national group
with expert local knowledge to define the level of local
funding required and seek the most appropriate source.
Funding may come from varying sources including
the core funding of the collaborative group, national
funding bodies and pharmaceutical market companies
where relevant. The relative cost of running a trial
may vary considerably between countries. The UK
makes a distinction between commercial and non-
commercial trials with an associated differential in
costing and infrastructure support whilst many coun-
tries do not. There may also be added complexities in
terms of good clinical practice (GCP) expectations;
whilst in the UK non-commercial trials may be run
according to the principles of GCP (as per Schedule
1 of the UK Medicines for Human Use (Clinical Tri-
als) Regulations 2004) many countries mandate
resource-intensive International Conference on Har-
monisation (ICH)-GCP, which may increase local trial
management costs (e.g. requiring 100% source data
verification during on-site monitoring).
Working with industry
Lack of sufficient funding is a recognised significant bar-
rier to global academic cancer research [12]. Pharma-
ceutical companies can offer funding to an order of
magnitude that enables international participation,
something that many charity and government grants are
unable to do. Academically sponsored trials are fre-
quently conducted in collaboration with industry part-
ners, and in these cases, the pharmaceutical company
can offer not just grant funding, but assistance in setting
up international participation. This can be in the form of
market companies offering funding to support local trial
management costs and in the planning and delivery of
international drug distribution, including advising the
sponsor on local drug labelling and import require-
ments. Local market companies can also provide support
in terms of local language, regulatory knowledge and
country-specific operational expertise.
Our success story
The path of ICR-CTSU’s international trial management
has by no means been straightforward but has been
forged on strong and numerous collaborations. The
CASPS trial of cediranib in patients with alveolar soft
part sarcoma (ISRCTN63733470) closed to recruitment
in July 2016, after reaching the required sample size of
just 48 patients over a period of 5 years. Alveolar soft
part sarcoma is rare, with an estimated incidence of only
15 cases per year in the UK. International participation
in this trial was therefore imperative and has been a re-
sult of extensive, numerous and complex collaborations.
To deliver the CASPS trial we received funding, support
and advice from a UK cancer charity, the pharma-
ceutical company partner, a drug distribution com-
pany, international academic groups, their respective
trials units and CROs, insurance brokers, contracts
teams and lawyers. ICR, as trial sponsor, contracted
directly with the pharmaceutical partner, the global
drug distribution company, UK participating sites and
the international collaborative groups. The collabora-
tive groups obtained funding for local trial conduct
and contracted with participating sites in their coun-
tries. A single global protocol existed with country-
specific requirements for conduct detailed in support-
ing trial guidance notes to control the number of
amendments. Country-specific approvals were ob-
tained by the relevant collaborative group with sup-
port from ICR-CTSU to ensure consistency of
applications. Trial operating procedures, for example
for trial monitoring, were developed in collaboration
with each collaborative group to allow for country-
specific requirements. Collaborative groups provided
trial approvals, monitoring reports and progress re-
ports to ICR-CTSU to allow sponsor oversight glo-
bally throughout the life of the trial. This approach
ensured clear lines of communication existed and trial
conduct was consistent across participating countries.
CASPS is the first international randomised trial to
be conducted successfully in this rare disease.
International trial collaboration recommendations
Table 1
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Conclusion
Conducting international trials can be challenging for aca-
demic sponsors but can be achieved through appropriate
governance arrangements, funding mechanisms and
strong collaborations with international collaborative trials
groups, and industry where applicable. CASPS is an excel-
lent example of how such collaborations have helped to
deliver an academic trial internationally. In trials of rare
cancers where the sample size is comparatively small, al-
though the required investment can seem disproportion-
ate and difficult to justify, it is essential if progress is to be
made in these areas of unmet clinical need.
Abbreviations
CRO: Contract research organisation; GCP: Good clinical practice; ICH-
GCP: International conference on harmonisation good clinical practice;
ICR: The Institute of Cancer Research; ICR-CTSU: The Institute of Cancer




The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)
is supported by a core programme grant (grant number C1491/A15955)
from Cancer Research UK.
Availability of data and materials
Not applicable.
Authors’ contributions
LF, CT, SK, CS and JMB contributed to manuscript writing and review. All
authors read and approved the final manuscript.
Authors’ information
Not applicable.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 19 May 2017 Accepted: 11 September 2017
References
1. Shash E, Negrouk A, Marreaud S, Golfinopoulos V, Lacombe D, Meunier F.
International clinical trials setting for rare cancers: organisational and
regulatory constraints—the EORTC perspective. Ecancermedicalscience.
2013;7:321.
2. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin
E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V,
Kurzrock R. Challenges in initiating and conducting personalized cancer
therapy trials: perspectives from WINTHER, a worldwide innovative network
(WIN) consortium trial. Ann Oncol. 2015;26:1791–8.
3. Kempf L, Goldsmith JC and Temple R. Challenges of developing and
conducting clinical trials in rare disorders. Am J Med Genet A. 2017; doi: 10.
1002/ajmg.a.38413.
4. Marshall JC. Global collaboration in acute care clinical research:
opportunities, challenges, and needs. Crit Care Med. 2017;45(2):311–20.
5. Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E,
Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM,
Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS,
Meunier F. Improving cancer outcomes through international collaboration
in academic cancer treatment trials. J Clin Oncol. 2009;27(30):5109–14.
6. Glover M, Buxton M, Guthrie S, Hanney S, Pollitt A, Grant J. Estimating the
returns to UK publicly funded cancer-related research in terms of the net
value of improved health outcomes. BMC Med. 2014;12:99.
7. Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R,
Aranda E, Marais R and Stahel R. Safeguarding the future of independent,
academic clinical cancer research in Europe for the benefit of patients.
ESMO Open 2017. DOI: 10.1136/esmoopen-2017-000187.
8. UKCRC Clinical Trials Units Network. 2017. http://www.ukcrc-ctu.org.uk/.
Accessed 6 Sept 2017.
9. National Cancer Research Institute. Clinical Trials Group. 2017. http://www.
ncri.org.uk/accelerating-cancer-research/ctu/. Accessed 6 Sept 2017.
10. Miossec M, Miossec P. New regulatory rules for clinical trials in the United
States and the European union: key points and comparisons. Arthritis
Rheum. 2006;54(12):3735–40.
11. Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA,
Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The globalization of
cooperative groups. Semin Oncol. 2015;42(5):693–712.
12. Seruga B, Sadikov A, Cazap EL, Delgado LB, Digumarti R, Leighl NB, Meshref
MM, Minami H, Robinson E, Yamaguchi NH, Pyle D, Cufer T. Barriers and
challenges to global clinical cancer research. Oncologist. 2014;19(1):61–7.
Table 1 Recommendations based on the ICR-CTSU experience
Operational area Challenges Recommendations
Sponsorship Co-sponsorship not currently recognised outside
UK.
Institution to define requirements for sole sponsorship (NB. Co-
sponsorship to be recognised in new EU regulation No 536/2014).
Country selection Resource requirements increase with each
participating country.
Careful consideration of the minimum number of countries required




Not all groups are willing or able to take on the
required country-specific sponsor responsibilities.
Define detailed, accurate and clear country-specific responsibilities
early in negotiations.
Insurance Country-specific insurance requirements are
complex and expensive.
Work closely with specialist insurance broker with relevant experience.
Working with North
America
Regulatory, data protection and insurance
requirements can be prohibitive.
Seek alternative models of collaboration to sponsoring a trial in the
US e.g. run parallel trials with the same protocol and database.
Funding Central funding is not always sufficient to cover
local costs.
Highlight possible funding shortfalls to collaborative groups early in
discussions and ensure all funding requirements can be met within
the proposed study timelines.
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